Phenyl-thiophene type vitamin D receptor modulators

Details Phenyl-thiophene type vitamin D receptor modulators Phenyl-thiophene type vitamin D receptor modulators

2003-05-22

2009-10-13

Anderson, Rebecca L (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07601850

ABSTRACT:
The present invention relates to novel, non-secosteroidal, phenyl-thiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

REFERENCES:
patent: 2831859 (1958-04-01), Werner et al.
patent: 5300499 (1994-04-01), Chow
patent: 6288277 (2001-09-01), Anderskewitz et al.
patent: 6706725 (2004-03-01), Bernardon
patent: 2006/0094778 (2006-05-01), Nagpal et al.
patent: 2006/0135484 (2006-06-01), Nagpal et al.
patent: 2006/0293385 (2006-12-01), Gajewski et al.
patent: 2007/0105951 (2007-05-01), Gajewski et al.
patent: 2007/0106095 (2007-05-01), Lu et al.
patent: 2007/0149810 (2007-06-01), Lu et al.
patent: 2007/0225377 (2007-09-01), Flatt
patent: WO 00/10958 (2000-03-01), None
patent: WO 01/38320 (2001-05-01), None
patent: WO 2004/048309 (2004-06-01), None
patent: WO 2005/051893 (2005-06-01), None
patent: WO 2006/069153 (2006-06-01), None
patent: WO 2006/069154 (2006-06-01), None
Skin cancer [online], [retrieved on Mar. 12, 2008]. Retrieved from the Internet, URL; http://www.healthline.com/adamcontent/skin-cancer?utm—medium=ask&utm—source=sma . . . .
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992-1996.
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 2050-2057.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet, URL; http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimer's.drug.ap/index.html>.
Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3, Boehm, et al., Chemistry & Biology, vol. 6, No. 5, pp. 265-275 (1999).
Condensation of Some Alkenylthiophenes with Phenol and Hexachlorocyclpentadiene, Torikov, et al., Bashkir Republic Board, All-Union Chemical Society named for D.I. Mendeleev, Reports of Petrochemical Section No. 6, 1971.
Chem. Abst. No. 77:164354, Torikov, et al.,Condensation of Some Alkenylthiophenes with Phenol and Hexachlorocyclpentadiene, 1971.
Nagpal, S. et al. “Vitamin D Analogs: Mechanism of Action of Therapeutic Applications”,Curr. Med. Chem. 2001, 1661-1679, vol. 8.
Bouillon R., et al. Structure-Function Relationships in the Vitamin D Endocrine System, Endocrine Rev. 1995, 200-257, vol. 16.
Swann et al. “Rational Design of Vitamin D3 Analogues Which Selectively Restore Activity to a Vitamin D Receptor Mutant Associated with Rickets”Org. Lett. 2002, p. 1863-3866 vol. 4.
Swann et al. “Structure-Based Design of Selective Agonists for a Rickets-Associated Mutant of the Vitamin D Receptor”J. Am. Chem. Soc. 2002 13795-13805, vol. 124.
Basak, et al., “Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp,”European Academy of Dermatology and Venereology JEADV, vol. 15, pp. 77-92 (2001).
Böhm, et al., “Disseminated superficial actinic porokeratosis: Treatment with topical tacalcitol,”Journal of the American Academy of Dermatology, vol. 40, pp. 479-480 (1999).
Cunningham, et al., “Topical calcipotriene for morphea/linear scleroderma,”Journal of the American Academy of Dermatology, vol. 39, pp. 211-215 (1998).
Harrison, “Disseminated superficial actinic porokeratosis responding to calcipotriol,”Clinical Exp. Dermatol., vol. 19, No. 1, p. 95 (1994).
Lin, et al., “The pleiotropic actions of vitamin D,”BioEssays, vol. 26, pp. 21-28 (2003).
Nakayama, et al., “Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24(R)-dihydroxycholecalciferol (tacalcitol) cream,”European Journal of Dermatology, vol. 10, No. 7, pp. 528-532, (2000).
Sapadin, et al., “Treatment of Scleroderma,”Arch Dermatology, vol. 138, pp. 99-105 (2002).
Sato, et al., “Epidermal Growth Factor and 1α,25-Dihydroxyvitamin D3Suppress Kipogenesis in Hamster Sebaceous Gland Cells In Vitro,”The Society of Investigative Dermatology, vol. 117, pp. 965-970 (2001).
Zinser, et al., “Vitamin D3receptor ablation sensitizes skin to chemically induced tumorigenesis,”Carcinogenesis, vol. 23, No. 12, pp. 2103-2109 (2002).
Comedolytic effect of topically applied active vitamin D3analogue on pseudocomedones in the rhino mouse, Hayashi et al., British Journal of Dermatology 2006, 155, pp. 895-901.
Transcriptional Profiling of Keratinocytes Reveals a Vitamin D-Regulated Epidermal Differentiation Network, Lu, et al., J Invest Dermatol 124:778-785 (2005).
Vitamin D and the skin: an ancient friend, revisited, Reichrath, J. Experimental Dermatology, 16, 618-625 (2007).
Vitamin D Receptor Modulators for Inflammation and Cancer, Yee, et al., Mini-Reviews in Medicinal Chemistry, 2005, 5, 761-778.
Sunlight, Vitamin D, and the Innate Immune Defenses of the Human Skin, Zasloff, M., The Society for Investigative Dermatology, Inc., pp. xvi, (2005).
The Organic Chemistry of Drug Design and Drug Action, 2ndEd., pp. 29-34, Elsevier Academic Press (2004).

Affiliated with

Also associated with

Rating

Phenyl-thiophene type vitamin D receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phenyl-thiophene type vitamin D receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenyl-thiophene type vitamin D receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4054656